LivaNova(US:LIVN)2026-02-25 14:02Financial Data and Key Metrics Changes - In Q4 2025, revenue was $361 million, reflecting a 9.5% increase on a constant currency and organic basis compared to the prior year [22] - Adjusted diluted earnings per share increased to $0.86 from $0.81 in Q4 2024, driven by strong revenue growth and effective cost management [24] - Cash balance at December 31, 2025, was $636 million, up from $429 million at year-end 2024, reflecting improved operating cash flows [25] - Total debt decreased to $377 million from $628 million at year-end 2024 due to early repayments [25] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue was $207 million in Q4 2025, a 10% increase year-over-year, with full-year revenue growing 13% [8] - Epilepsy segment revenue increased by 9% in Q4 2025, with full-year revenue growth of 6% [10][11] - Cardiopulmonary consumables revenue grew in the mid-teens in Q4, driven by market share gains and strong demand [9] Market Data and Key Metrics Changes - U.S. epilepsy revenue grew 8% year-over-year, while Europe and Rest of World regions combined saw a 17% increase [10] - The reimbursement for VNS Therapy procedures under Medicare increased significantly, with hospital outpatient payments rising by approximately 48% for new patient implants [12] Company Strategy and Development Direction - The company aims to transform into a best-in-class med tech company, focusing on high-growth markets like obstructive sleep apnea (OSA) [6] - Investments in innovation and digital platforms are prioritized to enhance patient access and improve care pathways [7] - The company plans to leverage competitive advantages through disciplined capital allocation and focused execution [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained value for shareholders, highlighting strong execution across core businesses [31] - The company anticipates continued growth driven by healthy markets and strategic investments in innovation [14] - Management remains optimistic about the potential of the OSA market, viewing it as a compelling opportunity [17] Other Important Information - The company expects full-year 2026 revenue growth between 6% and 7%, consistent with the 2025 to 2028 framework [30] - Adjusted free cash flow for 2026 is projected to be in the range of $160 million to $180 million, reflecting increased capital spending [28] Q&A Session Summary Question: Insights on cardiopulmonary growth guidance for FY 2026 - Management expects continued growth drivers from Essenz upgrades, market share gains, and pricing strategies [35] Question: Clarification on epilepsy business guidance - Management noted significant tailwinds from improved reimbursement and clinical evidence, which are expected to support growth [42] Question: Impact of reimbursement changes on VNS business - Management indicated no significant negative impact from recent reimbursement changes, with ongoing efforts to improve penetration [49] Question: Specifics on tender timing and geographic impact - Management confirmed that the shift in placements was immaterial and will be fully captured in Q1 2026 [38] Question: Updates on Medicaid reimbursement changes - Management stated that Medicaid is expected to follow Medicare reimbursement improvements over time [83]